(Bloomberg) --
Sanofi's two Covid-19 vaccines are entering new phases of trials in coming weeks and both could be available by the end of the year, said Thomas Triomphe, head of Sanofi Pasteur.
Sanofi's more advanced vaccine candidate, being jointly developed with GlaxoSmithKline Plc, will enter another Phase II trial later this month, and there have been no problems with getting the right formulations, Triomphe said in a phone interview. His comments came in response to an earlier report in French weekly Journal du Dimanche, questioning whether they would be ready.
The company's messenger RNA-based vaccine candidate -- being jointly developed with Translate Bio Inc. -- will probably enter early stage trials in March and could be approved by end of year if regulators don't demand large-scale late-stage trials, he said.
©2021 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
